FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206472> ?p ?o ?g. }

• W4387206472 endingPage "e101" @default.
• W4387206472 startingPage "e100" @default.
• W4387206472 abstract "Given the increased brain penetrance of osimertinib, the role of upfront radiotherapy (RT) has been questioned for the management of patients with EGFR+ NSCLC brain metastases (BM). We conducted a multi-institutional review of patients with EGFR+ NSCLC treated with upfront osimertinib or osimertinib in combination with RT for new or progressing BM.Our multi-institutional analysis included 128 patients with 714 BM treated between 2013 and 2022. Two BM treatment groups were evaluated: (1) upfront osimertinib alone (n = 66) and (2) osimertinib + RT [whole brain radiation therapy or stereotactic/fractionated radiosurgery (SRS/FSRT)] prior or concurrently with osimertinib (n = 62)]; both groups began treatment within 2 months of BM diagnosis. Time-to-event analysis was conducted with the Kaplan-Meier (KM) method, and outcomes included intracranial control (IC) [both local and distant], intracranial progression free survival (IPFS), and overall survival (OS). A Cox proportional hazards model was utilized for multivariate analysis (MVA).Median follow-up from BM diagnosis was 33.9 months (0.13-76.2 months). No differences in age (p = 0.46), sex (p = 0.72), DS-GPA (p = 0.08), KPS (p = 0.57), number of BM (p = 0.19) or volume of BM (p = 0.45), RT dose (p = 0.45), number of systemic metastases (p = 0.88), and patients symptomatic at presentation (p = 1.0) were noted. Prior treatment of BM was more common in the osimertinib + RT group (50% osimertinib + RT and 27% osimertinib; p = 0.01). The 12-month KM rates for osimertinib vs osimertinib + RT groups for IC were 72% vs 73% (p = 0.33); IPFS 53% vs 66% (p = 0.007); and OS 65% vs 80% (p = 0.025). On MVA, higher KPS (p = 0.002) was associated with increased OS and no extracranial metastasis with increased OS (p = 0.01) and IPFS (p = 0.001). MVA showed no association between osimertinib vs osimertinib + RT for IC, IPFS, or OS. Of the 66 patients treated with upfront osimertinib, 18 patients (27%) with 31 lesions eventually required RT for intracranial progression with the majority 72% being treated with SRS/FSRT at median of 13.5 months (1-22 months) following the start of osimertinib.This study suggests that upfront osimertinib alone may provide sufficient intracranial control to allow RT to be deferred until further intracranial progression in select patients. Prospective trials are warranted to further guide treatment." @default.
• W4387206472 created "2023-09-30" @default.
• W4387206472 creator A5001987828 @default.
• W4387206472 creator A5003748444 @default.
• W4387206472 creator A5030440776 @default.
• W4387206472 creator A5030668094 @default.
• W4387206472 creator A5034442780 @default.
• W4387206472 creator A5036139080 @default.
• W4387206472 creator A5062612957 @default.
• W4387206472 creator A5062773129 @default.
• W4387206472 creator A5074650908 @default.
• W4387206472 creator A5087818066 @default.
• W4387206472 creator A5091280788 @default.
• W4387206472 date "2023-10-01" @default.
• W4387206472 modified "2023-10-17" @default.
• W4387206472 title "Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series" @default.
• W4387206472 doi "https://doi.org/10.1016/j.ijrobp.2023.06.869" @default.
• W4387206472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784626" @default.
• W4387206472 hasPublicationYear "2023" @default.
• W4387206472 type Work @default.
• W4387206472 citedByCount "0" @default.
• W4387206472 crossrefType "journal-article" @default.
• W4387206472 hasAuthorship W4387206472A5001987828 @default.
• W4387206472 hasAuthorship W4387206472A5003748444 @default.
• W4387206472 hasAuthorship W4387206472A5030440776 @default.
• W4387206472 hasAuthorship W4387206472A5030668094 @default.
• W4387206472 hasAuthorship W4387206472A5034442780 @default.
• W4387206472 hasAuthorship W4387206472A5036139080 @default.
• W4387206472 hasAuthorship W4387206472A5062612957 @default.
• W4387206472 hasAuthorship W4387206472A5062773129 @default.
• W4387206472 hasAuthorship W4387206472A5074650908 @default.
• W4387206472 hasAuthorship W4387206472A5087818066 @default.
• W4387206472 hasAuthorship W4387206472A5091280788 @default.
• W4387206472 hasBestOaLocation W43872064721 @default.
• W4387206472 hasConcept C121608353 @default.
• W4387206472 hasConcept C126322002 @default.
• W4387206472 hasConcept C143998085 @default.
• W4387206472 hasConcept C2777626846 @default.
• W4387206472 hasConcept C2778087573 @default.
• W4387206472 hasConcept C2779438470 @default.
• W4387206472 hasConcept C2780387249 @default.
• W4387206472 hasConcept C509974204 @default.
• W4387206472 hasConcept C71924100 @default.
• W4387206472 hasConceptScore W4387206472C121608353 @default.
• W4387206472 hasConceptScore W4387206472C126322002 @default.
• W4387206472 hasConceptScore W4387206472C143998085 @default.
• W4387206472 hasConceptScore W4387206472C2777626846 @default.
• W4387206472 hasConceptScore W4387206472C2778087573 @default.
• W4387206472 hasConceptScore W4387206472C2779438470 @default.
• W4387206472 hasConceptScore W4387206472C2780387249 @default.
• W4387206472 hasConceptScore W4387206472C509974204 @default.
• W4387206472 hasConceptScore W4387206472C71924100 @default.
• W4387206472 hasIssue "2" @default.
• W4387206472 hasLocation W43872064721 @default.
• W4387206472 hasLocation W43872064722 @default.
• W4387206472 hasOpenAccess W4387206472 @default.
• W4387206472 hasPrimaryLocation W43872064721 @default.
• W4387206472 hasRelatedWork W2046609575 @default.
• W4387206472 hasRelatedWork W2137559107 @default.
• W4387206472 hasRelatedWork W2147686964 @default.
• W4387206472 hasRelatedWork W2163132578 @default.
• W4387206472 hasRelatedWork W2384708512 @default.
• W4387206472 hasRelatedWork W2388910868 @default.
• W4387206472 hasRelatedWork W2900090871 @default.
• W4387206472 hasRelatedWork W3030041872 @default.
• W4387206472 hasRelatedWork W3197306284 @default.
• W4387206472 hasRelatedWork W4295168981 @default.
• W4387206472 hasVolume "117" @default.
• W4387206472 isParatext "false" @default.
• W4387206472 isRetracted "false" @default.
• W4387206472 workType "article" @default.